Completed PHASE2 INTERVENTIONAL 2-arm NCT01333540

A Study to Assess the Safety, Tolerability and Clinical Activity of TD-1211 in Patients With Opioid-Induced Constipation

A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Study to Assess the Safety, Tolerability, and Clinical Activity of TD-1211 in Subjects With Opioid-Induced Constipation

Sponsor: Theravance Biopharma

Conditions Opioid-induced Constipation (OIC)

Interventions Placebo TD-1211

Updated 11 times since 2017 Last updated: Jan 19, 2021 Started: May 31, 2011 Primary completion: May 31, 2012 Completion: Jun 30, 2012

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Opioid-induced Constipation (OIC), this trial is completed. The trial is conducted by Theravance Biopharma and has accumulated 11 data snapshots since 2011. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

11 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Apr 2022 — Jul 2024 [monthly]

Completed PHASE2
Feb 2021 — Apr 2022 [monthly]

Completed PHASE2
Jan 2021 — Feb 2021 [monthly]

Completed PHASE2

▶ Show 6 earlier versions

Sep 2020 — Jan 2021 [monthly]

Completed PHASE2
Feb 2019 — Sep 2020 [monthly]

Completed PHASE2
Oct 2018 — Feb 2019 [monthly]

Completed PHASE2
Jun 2018 — Oct 2018 [monthly]

Completed PHASE2
Feb 2017 — Jun 2018 [monthly]

Completed PHASE2
Jan 2017 — Feb 2017 [monthly]

Completed PHASE2

First recorded

May 2011

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Theravance Biopharma

Data source: Theravance Biopharma

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Salt Lake City, United States